SCHEMBL1940360

SCHEMBL1940360

COc1cc2nc(Cl)nc(-c3cccc(Oc4ccccc4)c3)c2cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WHR1 P49842 2/20 0.55
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
ADORA2A P29274 1/20 0.46
TP53 P04637 1/20 0.45
EGFR P00533 2/20 0.44
LCK P06239 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
MAT2A P31153 1/20 0.42
RIPK2 O43353 1/20 0.42
EPHB2 P29323 1/20 0.42
PDE4A P27815 1/20 0.42
PDE4D Q08499 1/20 0.42
DHODH Q02127 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27117202 0.90 WHR1 (0.53) WHR1KDM4EALDH1A1LMNAMAPT
SCHEMBL1941112 0.87 WHR1 (0.60) WHR1KDM4EALDH1A1LMNAMAPT
SCHEMBL27117037 0.87 WHR1 (0.71) WHR1KDM4EALDH1A1LMNAMAPT
SCHEMBL1941739 0.85 PDGFRB (0.50) WHR1KDM4EALDH1A1LMNAMAPT
SCHEMBL6779398 0.83 PDE4A (0.56) WHR1MAPTADORA2ATP53EGFR
SCHEMBL27777423 0.81 EGFR (0.47) WHR1KDM4EALDH1A1LMNAMAPT
SCHEMBL295421 0.81 WHR1 (0.52) WHR1KDM4EALDH1A1LMNAMAPT
SCHEMBL1941684 0.81 WHR1 (0.52) WHR1KDM4EALDH1A1LMNAMAPT
SCHEMBL1942127 0.79 WHR1 (0.53) WHR1KDM4EALDH1A1LMNAMAPT
SCHEMBL1942856 0.79 WHR1 (0.56) WHR1KDM4EALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1052254-B1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND MEDICINE THEREOF EISAI R&D MAN CO LTD (JP) 2011-06-15 EP disclosed
US-6800644-B2 PHOSPHODIESTERASE-4 INHIBITOR, AMINOQUINOLINE OR AMINOISOQUINOLINE DERIVATIVES EISAI CO., LTD. (JP) 2004-10-05 US disclosed
US-20020055516-A1 Nitrogen-containing heterocyclic compounds and medicaments containing the compounds EISAI CO., LTD. 2002-05-09 US disclosed
US-6352989-B1 ENZYME INHIBITORS FOR PHOSPHODIESTERASE EISAI CO., LTD. (JP) 2002-03-05 US disclosed
EP-1052254-A1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND MEDICINE THEREOF Eisai Co., Ltd. (JP) 2000-11-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055516-A1 Nitrogen-containing heterocyclic compounds and medicaments containing the compounds PDE4A, PDE4B, PDE5A WHR1 3881/4885KDM4E 612/4885ALDH1A1 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.